Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(2;5; p23;q35) that produces the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma kinase). NPM-ALK-deregulated kinase activity drives several pathways that support malignant transformation of lymphoma cells. We found that in ALK-rearranged ALCL cell lines, NPM-ALK was distributed in equal amounts between the cytoplasm and the nucleus. Only the cytoplasmic portion was catalytically active in both cell lines and primary ALCL, whereas the nuclear portion was inactive because of heterodimerization with NPM1. Thus, about 50% of the NPM-ALK is not active and sequestered as NPM-ALK/NPM1 heterodimers in the nucleus. Overexpression or relocalization of NPM-ALK to the cytoplasm by NPM genetic knockout or knockdown caused ERK1/2 (extracellular signal-regulated protein kinases 1 and 2) increased phosphorylation and cell death through the engagement of an ATM/Chk2-and γH2AX (phosphorylated H2A histone family member X)-mediated DNA-damage response. Remarkably, human NPM-ALK-amplified cell lines resistant to ALK tyrosine kinase inhibitors (TKIs) underwent apoptosis upon drug withdrawal as a consequence of ERK1/2 hyperactivation. Altogether, these findings indicate that an excess of NPM-ALK activation and signaling induces apoptosis via oncogenic stress responses. A 'drug holiday' where the ALK TKI treatment is suspended could represent a therapeutic option in cells that become resistant by NPM-ALK amplification.
INTRODUCTION
Recurrent genetic alterations of the anaplastic lymphoma kinase (ALK) gene on chromosome 2 have been reported in different hematological and solid tumors. 1, 2 The t(2;5) is by far the most frequent translocation in anaplastic large-cell lymphoma (ALCL) involving the nucleophosmin (NPM1) gene as a partner of translocation. 1, 3 Several other partner genes have been described in ALCL and other tumors. 2 All ALK fusion partners contain domains that allow the dimerization of the fusion chimera and the activation of the ALK kinase. NPM-ALK spontaneously dimerizes through the NPM1 oligomerization domain, transphosphorylates the kinase domain and activates downstream pathways that sustain lymphoma cell proliferation and survival. Cellular localization of ALK fusions depends on the fusion partner and the majority of ALK chimeras are entirely cytoplasmic. 1, 4 NPM-ALK is the only ALK chimera localized in both the cytoplasm and the nucleus. Previous works demonstrated that the cytoplasmic localization of ALK fusions is required for cellular transformation, 5, 6 but no precise role has yet been assigned to the nuclear NPM-ALK or to the balance between its nuclear and cytoplasmic fractions. Understanding the functions of the NPM-ALK cell fractions could be exploited in the development of new therapeutic strategies that interfere with the physiological balance of NPM-ALK cytoplasmic and nuclear fractions in ALCL. Indeed, drugs that inhibit nuclear-cytoplasmic transport, the so-called selective inhibitors of nuclear export, have shown strong antitumoral activity in preclinical in vitro and in vivo studies and are currently in early-phase clinical trials for advanced hematological malignancies and solid tumors. 7, 8 Moreover, previous studies demonstrated that in chronic myelogenous leukemia the combined use of imatinib, the selective inhibitor of the chronic myelogenous leukemia oncogenic driver kinase BCR-ABL, and leptomycin B, a 'precursor' molecule of selective inhibitors of nuclear export, was more effective in killing cells than the inhibitor alone. 9 The recent discovery of specific ALK tyrosine kinase inhibitors (TKIs) has markedly changed the way patients bearing ALKrearranged tumors are treated. 10, 11 In ALK-rearranged non-smallcell lung cancer (NSCLC), crizotinib as well as next-generation ALK TKIs such as ceritinib, alectinib or brigatinib have proven to have clinical efficacy. [12] [13] [14] Unfortunately, each TKI treatment is invariably associated with the development of TKI resistance and NSCLC relapse. [15] [16] [17] [18] Similarly to NSCLC patients, crizotinib resistance occurs in a fraction of ALCL patients. 19 Understanding the mechanisms of ALK TKI resistance is critical to envision new treatment strategies to maximize the clinical benefits for ALK-rearranged ALCL patients. To date, most of the data on the mechanisms of resistance to ALK TKI have been collected in NSCLC patients, [20] [21] [22] [23] whereas very few data are available for ALCL. Mechanisms of acquired resistance to ALK TKI in ALK-rearranged ALCL have been described mainly in vitro by our group and others, including single point mutations of the TK domain and amplification of the ALK fusion gene. [24] [25] [26] [27] [28] Amplification of the ALK fusion gene has also been described in ALK-rearranged NSCLC and leads to increased expression of the oncogenic ALK fusion that requires increasing dosage of ALK TKI to be treated. Overexpression of a driver oncogene as a mechanism of resistance to TKI has also been reported in chronic myelogenous leukemia patients treated with imatinib. 29 Remarkably, acute overactivation following imatinib suspension in BCR-ABL-amplified imatinib-resistant cells induces apoptosis of resistant cells. [29] [30] [31] In another notable example, melanoma cells develop resistance to B-RAF inhibitors, and B-RAF TKI suspension in resistant cells induces cell toxicity mediated by an excess of B-RAF oncogenic signaling. 32 Similar observations have been described in a few other cancer models. 33, 34 Overall, these data indicate that an intermitting administration of a TKI could represent a therapeutic approach designed to overcome TKI resistance in different tumors.
In this study, we show that NPM-ALK is equally distributed between the cytoplasm and the nuclear fractions, where nuclear NPM-ALK is inactive. This nuclear sequestration is critical for optimal survival of ALCL cells because an excess of NPM-ALK signaling causes oncogenic toxicity by activation of the DNAdamage response pathway. Consistently, NPM-ALK-amplified ALCL cells that developed resistance to the TKI brigatinib underwent massive apoptosis upon TKI suspension because of an excess of NPM-ALK activation. Thus, periodic ALK TKI suspension, a so-called 'drug holiday', may represent an effective treatment for ALCL patients developing TKI resistance by ALK amplification.
RESULTS
NPM-ALK is equally localized in the cytoplasm and the nucleus of ALCL cells, but it is phosphorylated only in the cytoplasm NPM-ALK is by far the most frequent fusion in ALK-rearranged ALCL, yet the only one localized both in the cytoplasm and in the nucleus.
1,2 Previous works demonstrated that the cytoplasmic localization of ALK fusions is needed for cell transformation, but never fully elucidated the role of the nuclear fraction. 5, 6 Therefore, we first analyzed NPM-ALK subcellular localization to better investigate the role of its nuclear fraction. We found that in all ALK-rearranged ALCL cell lines, NPM-ALK fusion was equally distributed between the cytoplasm and the nucleus, as previously reported in one cell line, 5 but, surprisingly, only the cytoplasmic fraction was phosphorylated and thereby kinetically active ( Figure 1a) . Consistently, a phospho-ALK (Y1604) antibody stained only the cytoplasm in primary ALK-rearranged ALCL, indicating that the NPM-ALK nuclear fraction was not active (Figure 1b) . Thus, despite NPM-ALK is expressed in equal amounts in the cytoplasm and in the nucleus in ALCL cells, only the half cytoplasmic fraction of the total NPM-ALK protein is catalytically active.
Enforced expression of NPM-ALK in the nucleus does not transform cells In the NPM-ALK fusion, NPM1 is truncated by the t(2;5) translocation before the nuclear (NLS) and the nucleolar localization signals (NuLS) (Figure 1c) . Thus, we reasoned that NPM-ALK can enter the nucleus only as a heterodimer with wild-type NPM1 (WT NPM1), and that these nuclear heterodimers are inactive because of the lack of transphosphorylation. To test this hypothesis, we first generated a fusion NPM-ALK construct containing the total NPM1 protein (NPM tot -ALK) (Figure 1c) . When expressed in 293 T cells, NPM tot -ALK localized entirely to the nucleus and the nucleolus because of the now conserved NPM1 NLS and NuLS, whereas NPM-ALK localized both in the cytoplasm and in the nucleus (Figure 1d and Supplementary Figures 1A and B ). Next, we tested the cell transformation potential of NPM tot -ALK in two independent assays. First, we stably transduced NPM-ALK, the kinase dead mutant K210R (NPM-ALK KD ) and NPM tot -ALK constructs into NIH3T3 cells and performed an anchorageindependent cell growth assay. NIH3T3 cells expressing the NPM tot -ALK showed limited anchorage-independent growth with few colonies growing in soft agar similar to the inactive NPM-ALK KD , strikingly less than NIH3T3 cells expressing oncogenic NPM-ALK (Figures 1e and f) . Second, we used the murine interleukin-3 (IL-3)-dependent pro-B cell line Ba/F3. In this assay, the ectopic expression of NPM-ALK enabled Ba/F3 cells to grow in the absence of IL-3, whereas neither NPM-ALK KD nor NPM tot -ALK did (Figures 1g and h) (Figures 2a and b) . In NPM Thus, lack of NPM-ALK sequestration by WT NPM1 induces NPM-ALK accumulation in the cytoplasm, resulting in cell apoptosis rather than transformation.
We next investigated the effects of knocking down the endogenous WT NPM1 in ALK-rearranged ALCL cell lines. We transduced ALK-rearranged ALCL cell lines (SU-DHL-1, COST, TS and KARPAS 299) with two different short hairpin RNA (shRNA) targeting NPM1 (Figure 3a and Supplementary Figure 2A) . The ALK-negative ALCL cell line, FEPD, was used as control. When NPM1 was knocked down, NPM-ALK phosphorylation increased compared with control cells, as we observed in NPM − / − /p53 − / − MEFs, likely due to the accumulation of NPM-ALK homodimers in the cytoplasm (Figure 3a and Supplementary Figure 2A These results indicate that in the absence of WT NPM1, the amount of phosphorylated NPM-ALK increases and that the excess of NPM-ALK signaling could be responsible for ALCL apoptosis. Figure 4B) .
Consistent with the in vitro results, overexpression of NPM-ALK in ALK-rearranged ALCL cells completely impaired cell growth in vivo. Indeed, no tumors were detected in subcutaneous xenografts of SU-DHL-1 and COST after overexpression of NPM-ALK (Figures 4g and h) .
Overall, these data indicate that higher expression levels of NPM-ALK in ALCL induce a relative increase of the cytoplasmic portion likely because the stoichiometric balance between NPM1 and NPM-ALK is altered. The increased cytoplasmic NPM-ALK results in apoptosis and lymphoma growth impairment. Thus, sequestration of about 50% of the NPM-ALK fusion is necessary to maintain the proper amount of ALK signaling. Overexpression of NPM-ALK causes DNA damage and accumulation of γH2AX microfoci through activation of the MAPK pathway Because oncogenes can induce apoptosis or senescence in response to DNA damage through replicative stress, 36, 37 we asked whether an excess of NPM-ALK signaling would activate an oncogene-induced DNA-damage response. We observed that ALK-rearranged ALCL cells overexpressing NPM-ALK displayed increased phosphorylation of the H2A histone family member X (H2AX), a key protein in the DNA repair pathway, and accumulation of phosphorylated H2AX (γH2AX) microfoci in the nuclei at Figures 7A and B) .
As DNA damage generated by oncogenic stress results from the activation of one of two main DNA-damage checkpoint pathways, the ATM-Chk2 and the ATR-Chk1, [38] [39] [40] we investigated whether the overexpression of NPM-ALK was associated with the activation of ATM/ATR/Chk pathway. We found that overexpression of NPM-ALK led mainly to the phosphorylation of Chk2 more than Chk1 or RPA32 (Figure 5d and Supplementary Figure 5C ). We also observed that excessive NPM-ALK signaling caused marked increase in the phosphorylation of the MAPK-ERK1/2 (mitogenactivated protein kinase/extracellular signal-regulated protein kinases 1 and 2) pathway, which has been described to mediate oncogenic stress (Figure 5e and Supplementary Figures 5B and 6A ). 41 To test whether hyper stimulation of cells through MAPK pathway was responsible for the DNA damage and phosphorylation of H2AX, we treated cells with a specific MEK inhibitor, CI-1040 (PD184352). SU-DHL-1 and COST cells were induced with doxycycline for 24 h and concomitantly treated with CI-1040. In cells overexpressing NPM-ALK, the inhibition of MEK resulted in marked dephosphorylation of H2AX (Figure 5e) . Similarly, the ectopic expression of NPM-ALK in MAC-1 cells caused a strong activation of the MEK/ERK1/2 pathway and a marked increase in the phosphorylation of H2AX (Supplementary Figure 8B) . Inhibition of the MEK/ERK1/2 pathway decreased H2AX phosphorylation (Supplementary Figure 8B) . Thus, these data indicate that excess of NPM-ALK signaling induces a DNA-damage response that is mediated by the MEK/ERK1/2 pathway.
KARPAS 299 resistant to the ALK TKI brigatinib (AP26113) overexpress NPM-ALK and are TKI dependent We and others recently described genomic amplification of the ALK locus as a mechanism of ALK TKI resistance. 26, 28 We reported three ALK-rearranged cell lines (K299AR300A, K299AR300B, K299AR300C) whose resistance to the ALK inhibitor brigatinib The activation of the caspase-3/7 was analyzed using Caspase-Glo 3/7 Assay (Promega) and the Glomax multidetection system (d). Data are from three independent experiments. Statistical significance was calculated by Student's t-test, where **Po 0.005 and ****P o0.0001.
was mediated by genomic amplification that caused NPM-ALK overexpression (Figure 6a ). 26 Interestingly, in all resistant cell lines overexpressed, NPM-ALK was mainly localized in the cytoplasm both in the presence and in the absence of the inhibitor, a finding in line with our data on ectopic overexpression of NPM-ALK (Figures 4 and 6b) . Surprisingly, these cell lines showed the highest proliferative rate not in the absence of ALK TKI, but in the presence of low doses (40 nM) of brigatinib. Indeed, inhibitor dose-response curves showed an abnormal proliferative peak around 40 nM brigatinib in NPM-ALK-amplified ALCL but not in parental cells (Figure 6c ). The cells showed the same abnormal dose-response curves upon inhibition with other ALK TKIs (crizotinib, alectinib, ceritinib and ASP3026) or with a heat-shock protein 90 inhibitor (17-AAG) that causes NPM-ALK downregulation (Supplementary Figure 9) . Thus, these cell lines with amplified NPM-ALK not only were TKI resistant but also showed TKI dependency. Interestingly, in the presence of 40 nM brigatinib, NPM-ALK phosphorylation levels and downstream signaling, including ERK1/2 phosphorylation, were comparable to parental cell lines (Figures 6b and d) . Remarkably, upon drug withdrawal the cytoplasmic fraction of NPM-ALK in ALK-amplified cell lines became highly phosphorylated, caused hyperactivation of ERK1/2 and led to oncogenic stress through phosphorylation of H2AX, in keeping with the data in ALK-rearranged ALCL cell lines overexpressing NPM-ALK (Figures 6b and d) . As a consequence, apoptosis was induced markedly after 72 h of drug suspension (Figure 6e ). The same effect was observed in another ALKrearranged cell line resistant to the ALK inhibitor ASP3026 and SUPM2R1. We recently demonstrated that in this cell line TKI resistance was mediated by both ALK amplification and an ALK point mutation. 25 Also, in this cell line, TKI withdrawal was followed by increased cell death (Supplementary Figure 10) . Overall, these data indicate that in NPM-ALK-amplified resistant ALCL cells the increased expression of NPM-ALK fusion results in the accumulation of cytoplasmic NPM-ALK. In this condition, the excess ALK signaling is partially abrogated by low doses of ALK TKI, resulting in ALK phosphorylation and ERK1/2 signaling comparable to the parental cells. However, upon ALK TKI suspension, the excess NPM-ALK signaling secondary to the ALK amplification induces an oncogenic stress response with DNA damage and apoptosis.
Long-term suspension of ALK TKI selects cells with restored sensitivity Based on these results, we envisioned a therapeutic approach to overcome resistance mediated by ALK amplification in ALCL. Figures 6d and e) . In contrast, K299AR300A and K299AR300C, after an initial apoptotic response, recovered in the absence of the TKI (Figure 7a , right panels). Remarkably, sensitivity to brigatinib was restored in these cells that recovered after TKI suspension (K299AR300A − and K299AR300C − ; Figures 7b and c) . IC 50 (half-maximal inhibitory concentration) values for brigatinib of K299AR300A − and K299AR300C − were similar to the original for parental cells (6 and 7 versus 3 nM; Figure 7c ). Interestingly, in these cells, NPM-ALK overexpression was lost as its expression levels were again similar to the parental cell line (Figure 7d ). These results are in accordance with recent data reported by Amin et al. 28 on regression in mice of NPM-ALK-amplified ALCL xenografts upon TKI treatment suspension. These results suggest that ALK TKI resistance mediated by ALK amplification could be tamed by cycles of drug suspension, a so-called 'drug holiday' where ALK-amplified cells would die under an oncogenic stressmediated DNA damage.
DISCUSSION
In the present work, we demonstrated that the amount of cytoplasmic NPM-ALK in ALCL is critical for optimal lymphoma growth and survival. We showed that only half of the total NPM-ALK in ALCL is active in the cytoplasm in the form of homodimers, whereas WT NPM1 sequesters the other half in the form of inactive heterodimers. Therefore, in NPM-ALK-rearranged ALCL, a critical stoichiometric equilibrium is reached between WT NPM1 and oncogenic NPM-ALK, and a perturbation of such equilibrium in either directions results in diminished cell growth and viability. A decrease of NPM-ALK expression or activity results in lymphoma cell cycle arrest and apoptosis, as it has now been demonstrated in preclinical models and in clinical trials with ALK TKI. 19, [42] [43] [44] In the present study, we demonstrate that also an excess of NPM-ALK signaling is detrimental to ALCL growth by triggering d) and caspase-3/7 activation was analyzed using Caspase-Glo 3/7 Assay (Promega) and the Glomax multidetection system. Data are from one of three independent experiments. (g and h) NOD-SCID (nonobese diabetic/severe-combined immunodeficiency) mice were inoculated subcutaneously in both flanks with 10 6 ALK-rearranged ALCL inducible cell lines (SU-DHL-1 and COST). Tumor growth was measured at the indicated time points. Statistical significance was calculated by Student's t-test, where *P o0.05, **P o0.005 and ****P o0.0001.
an oncogene-induced stress response and apoptosis, and that nuclear sequestration of NPM-ALK is essential to maintain the optimal levels and to prevent an excess of ALK signaling (Figure 8 ).
Oncogenes trigger growth-promoting and antiapoptotic signals for malignant transformation and outgrowth, but under certain conditions they can also initiate cellular programs that lead to apoptosis or senescence. 36 This phenomenon known as were grown in the presence of doxycycline for 48 h and treated with the MEK inhibitor CI-1040 (1μM) for 24 h. Total cell lysates were immunoblotted with the indicated antibodies. Data are from one out of three independent experiments. Statistical significance was calculated by Student's t-test, where **P o0.05 and ****P o0.0001.
Excess NPM-ALK signaling is toxic in ALCL M Ceccon et al oncogenic stress is a common response to a cell replicative stress and DNA damage induced by the enforced proliferation caused by the deregulated oncogenic activity. Oncogenes activate an ATR/ATM-regulated DNA-damage response network that delays or prevents cancer progression in early phase until this checkpoint is compromised by genetic alterations that often result in modification of the ATM-Chk2-p53 pathway. 36, 38 In ALCL, the p53 pathway is rarely inactivated by mutations, 45 but it has been suggested that its activity is partially inactivated in an MDM2-and JNK-dependent manner. 46 Our data show that ALCLs are still susceptible to apoptosis induced by an oncogenic stress generated by an excess of NPM-ALK signaling. When NPM-ALK was overexpressed or redirected to the cytoplasm after elimination of the nuclear sequestration by NPM1 knockout, a DNAdamage response was readily demonstrated by phosphorylation of Chk2 and formation of γH2AX and 53BP1 nuclear foci. Similarly to other oncogenes, the NPM-ALK oncogenic stress response was mediated by hyperactivation of MEK/ERK1/2 signaling. 36, 47, 48 In the present work, we also asked whether these findings could be exploited for therapeutic purposes. Exciting advancements in the therapy of ALCL are seemingly at hand after the development of ALK TKI. Our group was the first to show that the firstgeneration ALK TKI crizotinib is potently active in ALCL patients relapsed after standard cytotoxic therapy. 19, 43 However, a fraction of patients relapse under therapy for the development of resistance to ALK TKI.
Studies in few patients, so far, confirmed that mechanisms of resistance in ALCL are similar to those that occur in ALKrearranged NSCLC. Most cases of resistance are mediated by point mutations in the ALK tyrosine kinase domain that affect the binding of the ALK TKI. 19, 24, 27 As an alternative mechanism, we recently demonstrated that resistance to the ALK TKI brigatinib can also originate from amplification of the NPM-ALK gene so that an increased amount of NPM-ALK is produced by the resistant cells. 26 In these amplified ALCL cells, the stoichiometric balance between NPM-ALK and WT NPM1 is altered by an excess of NPM-ALK expression due to gene amplification. In these conditions, we demonstrated that releasing ALK inhibition by brigatinib suspension induces a rebound excess of ALK signaling identical to ALCL where NPM-ALK is overexpressed. This signaling includes hyperphosphorylation of ERK1/2 and -H2AX and results in cell apoptosis. Long-term culture of resistant KARPAS 299 cells in the absence of the ALK TKI resulted in the selection and outgrowth of cells that showed restored sensitivity to brigatinib. In those cell lines NPM-ALK overexpression was abrogated, consistently with data shown. Thus, in line with other cases of resistance, such as B-Raf, BCR-ABL and others, [31] [32] [33] [34] 49 our data suggest that patients who have developed resistance to ALK TKI mediated by NPM-ALK amplification might benefit from cycles of administration and suspension of TKI treatment, the so-called 'drug holiday' therapy ( Figure 8) . 50, 51 Recently, a drug holiday approach for NPM-ALKamplified ALCL was also proposed by Amin et al. 28 with experiments in xenograft mouse models.
A second possible therapeutic application of our findings would involve the use of drugs that alter the nuclear import-export, thereby creating an imbalance between the amounts of nuclear and cytoplasmic NPM-ALK. In the case of NPM-ALK accumulation in the cytoplasm, an oncogenic stress response would be activated. In contrast, should NPM-ALK nuclear sequestration increase, the active cytoplasmic fraction would decrease. In either cases, cell viability would be affected as we showed in this study. To test this hypothesis, in preliminary experiments we tested the nuclear export inhibitor KPT330 on ALCL cells. KPT330 is currently in clinical trial for the treatment of acute leukemia. 8, 52 Treatment with KPT330 resulted in a marked apoptosis of ALCL cells (Supplementary Figure 11A) . Remarkably, KTP330 synergized with crizotinib in the induction of apoptosis (Supplementary Figures 11B and E) . Increased sensitivity to crizotinib suggests that KPT330 might decrease the amount of active cytoplasmic NPM-ALK by impeding the nuclear export. More detailed studies on this combination therapy are currently under way in our laboratory.
In conclusion, our findings establish a novel concept of a critical balance of NPM-ALK signaling in ALCL cells. Exploiting the imbalance created by NPM-ALK amplification in TKI-resistant ALCL by a period 'drug holiday' could represent an additional therapeutic strategy for the treatment of ALK-rearranged ALCL. 53 NPM tot -ALK construct was generated by PCR. The PCR product was cloned into PCRII vector using the T/A cloning technology (Invitrogen, Waltham, MA, USA) and then cloned into pallino retroviral vector at HindIII/XhoI sites.
MATERIALS AND METHODS

Cell lines and reagents
For the TetON system, NPM-ALK and NPM-ALK K210R were cloned into a modified pCCL vector containing the coding sequence of the EGFP-1 and the inducible bidirectional PBI-1 promoter that coexpress the cloned gene and EGFP-1, as reporter.
Lentiviral shRNA clones targeting NPM were obtained from Sigma. Retroviruses and lentiviruses were generated and cells were infected as previously described. 53 For the lentiviral-mediated inducible gene expression, cells were coinfected with pCCL lentiviruses and the rtTA regulator plasmid, according to the TetON strategy. 54 For cell-sorting enrichment, cells were induced with 1μg/ml doxycycline hyciclate for 12 h and sorted for GFP expression on a MoFlo HighPerformance Cell Sorter (Dako Cytomation, Carpinteria, CA, USA). Cells were analyzed for GFP content on a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and the CELLQuest (tm) software (BD Biosciences, Franklin Lakes, NJ, USA) was used for the data acquisition and analysis.
Cell apoptosis, caspase, proliferation and soft-agar assays Apoptosis was measured by flow cytometry after staining with 200 nM tetramethylrhodamine methyl ester (TMRM) or with Annexin V-Propidium Iodide Apoptosis Detection Kit (BD Biosciences), as described previously. 53 For caspase assay, the activity of caspase-3 and -7 was measured using Caspase-Glo 3/7 Assay (Promega, Fitchburg, MA, USA) and the Multidetection System Glomax (Promega). Proliferation and soft-agar assays were performed as described previously. 24 Each experiment was repeated two or three times, see figure legends.
Protein subcellular fractionation and immunoblotting
Cells were processed for the cytoplasm-nuclear fractionation by sequential step of lysis following NE-PER Kit (Thermo Scientific, Waltham, MA, USA) protocol. Total cell lysates were extracted as described previously. 53 Each experiment was repeated three times.
Immunohistochemistry and immunofluorescence
Immunohistochemical and immunofluorescence stainings were performed as described previously. 53 Coverslips were viewed using a Leica TCS SP2 laser-scanning confocal microscope (Leica Biosystems, Nussloch, Germany) driven by the Leica Confocal Software (Leica Biosystems); the images were acquired at room temperature, by means of a 63X PL APO objective, numerical aperture 1.32. Brightfield images were acquired on a Leica DM IRE2 microscope (Leica Biosystems) using a DC300F camera and analyzed with the IM 50 software (Leica Biosystems).
Immunoblotting and immunofluorescence antibodies Nussloch, Germany); anti-Chk2 (no. 05-649; Upstate, Merck Millipore, Darmstadt, Germany); anti-phospho-RPA32 (S4/S8) (no. A300-245 A; Bethyl Laboratories, Montgomery, TX, USA); anti-β-Tubulin (no. T4026; Sigma); anti-actin (no. A2066; Sigma); anti-hnRNP A2/B1 (no. AB6102; Abcam, Cambridge, UK); anti-NPM (no. 32-5200; Invitrogen).
Fluorescence in situ hybridization analysis
Fluorescence in situ hybridization analysis on K299AR300A, AR300B and AR300C cell lines was described previously. 26 Amplified NPM-ALK quantification was performed using the Metafer Slide Scanning System (MetaSystems Hard & Software GmbH, Altlussheim, Germany). The image acquisition and the analysis of the cells were performed automatically by using the Metafer Slide Scanning System (MetaSystems Hard & Software GmbH), connected to the motorized microscope Zeiss Axio Imager.Z2 (Carl Zeiss, Jena, Germany). Three-channel images of a predefined area of the samples were acquired at a magnification of x40. A 'Z-stack' acquisition mode was used for the Red and Aqua channels, to provide a tridimensional evaluation of the corresponding fluorescence in situ hybridization signals. The Red and Aqua fluorescence in situ hybridization signals that resided inside the DAPI (4',6-diamidino-2-phenylindole) counterstain contour of the selected cells were identified and counted by a sophisticated spotcounting algorithm (based on Horn-Schunck algorithm). The ratio between the Red and Aqua values was calculated for every cell, and a medium overall ratio for all the analyzed cells was then calculated and graphically reported by the software.
In vivo tumor challenge NOD-SCID (nonobese diabetic/severe-combined immunodeficiency) mice (Charles River Laboratories Italia S.p.A, Charles River Italia, Calco, Italia) were inoculated subcutaneously (N = 4 ctrl and N = 4 treated) and measured as described previously. 55 Mice were handled and treated in accordance with European Community guidelines.
Statistical analysis
Dose-response curves were analyzed using the GraphPad Prism 5 software (La Jolla, CA, USA). IC 50 indicates the concentration of inhibitor that gives half-maximal inhibition. Statistical significance was calculated with twosided Student's t-test. P-values o 0.05 were considered significant. Unless otherwise noted, data are presented as means ± s.d.
